Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Asterias closes $9.9mm RDO

Executive Summary

Regenerative medicine company Asterias Biotherapeutics Inc. netted $9.9mm through the registered direct offering of 4mm common shares at $2.60 (a 21% discount). Chardan was the placement agent. The company will use the proceeds to fund continued development of its Phase I/II ASTOPC1 stem cell therapy candidate for spinal cord injury. Asterias also has in its pipeline cell therapy compounds for leukemia (Phase II) and lung cancer (preclinical).
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies